Skip to main content

Maxwell (Max) Skor

Analyst

Morgan Stanley

Equibles does not estimate personal net worth.

About Maxwell (Max) Skor

Maxwell (Max) Skor is recorded as Analyst at Morgan Stanley. Maxwell (Max) Skor has spoken on 3 earnings calls and 1 other investor event across 4 companies, most recently for Ultragenyx Pharmaceutical Inc. on September 17, 2026. Those appearances were for Ultragenyx Pharmaceutical Inc. (RARE), Ascendis Pharma A/S (ASND), Crinetics Pharmaceuticals, Inc. and Cytokinetics Inc (CYTK). The companies whose calls Maxwell (Max) Skor spoke on are classified in the Healthcare sector.

Maxwell (Max) Skor on recent calls

“I was just wondering if you can provide any insights into gross-to-net, particularly in the early stages of the launch. Thanks.”
Analyst — Morgan Stanley, Ultragenyx Conference Call ·
“Just a quick one on your V-Path durability. I was just wondering if dropouts are still mostly during the titration phase, and if you can comment at all on how reauthorizations are trending.”
Analyst — Morgan Stanley, Q2 2026 Ascendis Pharma Earnings Conference Call ·
“So now that you've outlined the Phase 2-3 design today, were there any key learnings from the Lancet GRACE data or the FDA's RELA-CORLANT PRL that informed how you're thinking about clinically meaningful endpoints or just overall study structure?”
Analyst — Morgan Stanley, Crinetics Pharmaceuticals, Inc. Q4 FY2025 Earnings Call ·
“Could you just confirm whether there are any shared trial sites between Odyssey and Acacia, approximately how many, the percentage overlap, and if so, what potential impact that might have on, let's say, a placebo response or other factors relevant to interpreting Acacia Thank you.”
Analyst — Morgan Stanley, Cytokinetics Inc Q3 FY2025 Earnings Call ·

Affiliation history

  • Morgan Stanley

    Analyst

    Source not stated

    Current

Company network

Crinetics Pharmaceuticals, Inc.

Biotechnology · Healthcare

1 appearance Latest appearance 2026-02-26

Recent activity